Clinical Trials Browser

Phase 3 × INDUSTRY × Brentuximab Vedotin × Clear all

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Phase 3 Completed

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03138499 2024-01-10

CheckMate 812

Phase 3 Terminated

23 enrolled 14 charts

Hodgkin Disease

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

452 enrolled 16 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01100502 2021-05-14

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Phase 3 Completed

329 enrolled 15 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01578499 2021-01-05

ALCANZA

Phase 3 Completed

131 enrolled 24 charts

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell